Follicular lymphoma grade IIIb
ICD-10 C82.4 is a billable code used to indicate a diagnosis of follicular lymphoma grade iiib.
Follicular lymphoma grade IIIb is a subtype of non-Hodgkin lymphoma characterized by the proliferation of follicle center (germinal center) B-cells. It is classified as a high-grade lymphoma, indicating a more aggressive disease course compared to lower-grade follicular lymphomas. The disease typically presents with lymphadenopathy, which may be generalized or localized, and can involve extranodal sites. Patients may exhibit B-symptoms, including fever, night sweats, and unexplained weight loss, which are indicative of systemic involvement. Diagnosis is confirmed through histopathological examination, often requiring a biopsy of affected lymph nodes. Staging is crucial for treatment planning and is typically performed using the Ann Arbor system, which assesses the extent of lymph node involvement and any extranodal disease. Treatment protocols may include chemotherapy, immunotherapy, or a combination of both, often tailored to the individual patient’s disease characteristics and overall health status. The prognosis for patients with grade IIIb follicular lymphoma can vary significantly based on factors such as age, performance status, and response to initial therapy.
Comprehensive documentation of diagnosis, staging, treatment plans, and follow-up care.
Patients presenting with lymphadenopathy and B-symptoms, requiring biopsy and staging.
Ensure accurate coding of treatment regimens and monitoring for response to therapy.
Detailed pathology reports confirming diagnosis and grade of lymphoma.
Biopsy specimens from lymph nodes or extranodal sites for histological evaluation.
Clear documentation of histological findings to support coding and treatment decisions.
Used during treatment of follicular lymphoma grade IIIb.
Document the specific chemotherapy agents used and the patient's response.
Oncology specialists must ensure accurate coding of chemotherapy regimens.
Common treatment options include chemotherapy regimens such as R-CHOP, immunotherapy with monoclonal antibodies, and in some cases, stem cell transplantation. Treatment is tailored based on the patient's overall health and disease characteristics.
